Abstract

This month, a third agent joined vemurafenib and trametinib as a highly effective treatment for BRAF -mutated melanomas. In a prospective, randomized phase III study, the selective BRAF inhibitor dabrafenib was found to improve the survival of stage IV melanoma patients. The investigators …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call